Prochlorperazine
Prochlorperazine Basic information
- Product Name:
- Prochlorperazine
- Synonyms:
-
- 10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-
- 2-Chloro-10-(3-(1-methyl-4-piperazinyl)-propyl)-phenothiazine
- 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10h-phenothiazin
- 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-phenothiazin
- 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
- 2-Chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine
- 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine
- 3-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine
- CAS:
- 58-38-8
- MF:
- C20H24ClN3S
- MW:
- 373.94
- EINECS:
- 200-379-4
- Product Categories:
-
- COMPAZINE
- Organics
- Mol File:
- 58-38-8.mol
Prochlorperazine Chemical Properties
- Melting point:
- 228 °C
- Boiling point:
- 260-275 °C(Press: 2 Torr)
- Density
- 1.1679 (rough estimate)
- refractive index
- 1.6000 (estimate)
- storage temp.
- Refrigerator
- solubility
- Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
- pka
- pKa 8.1(H2O,t =24±1,I undefined) (Uncertain)
- form
- Solid
- color
- White to Yellow
- Water Solubility
- 14.96mg/L(24 ºC)
- BCS Class
- 2
- CAS DataBase Reference
- 58-38-8(CAS DataBase Reference)
- NIST Chemistry Reference
- Prochlorperazine(58-38-8)
Safety Information
- Hazardous Substances Data
- 58-38-8(Hazardous Substances Data)
- Toxicity
- LD50 oral in rat: 1800mg/kg
MSDS
- Language:English Provider:2-Chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
Prochlorperazine Usage And Synthesis
Uses
antiemetic, antipsychotic, treatment of vertigo
Uses
Prochlorperazine is antiemetic, antipsychotic; used in treatment of vertigo.
Definition
ChEBI: A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.
brand name
Compazine (GlaxoSmithKline).
Clinical Use
Nausea and vomiting
Labyrinthine disorders
Psychoses
Severe anxiety
Safety Profile
Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Experimental teratogenic and reproductive effects. Human systemic effects by ingestion: headache, blood pressure elevation. Implicated in aplastic anemia. When heated to decomposition it emits very toxic fumes of SOx, NOx, and Cl-.
Veterinary Drugs and Treatments
Prochlorperazine as a single agent is used in dogs and cats as an antiemetic. The only approved products for animals are combination products containing prochlorperazine, isopropamide, with or without neomycin (Darbazine?, Neo-Darbazine?—SKB Labs) which are no longer marketed in the USA. The approved indications for these products include: vomiting, non-specific gastroenteritis, drug induced diarrhea, infectious diarrhea, spastic colitis, and motion sickness in dogs and cats (injectable product only).
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with
tramadol; enhanced hypotensive and sedative
effects with opioids; increased risk of ventricular
arrhythmias with methadone.
Anti-arrhythmics increased risk of ventricular
arrhythmias with anti-arrhythmics that prolong
the QT interval, e.g. procainamide, disopyramide,
dronedarone and amiodarone - avoid with
amiodarone and dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with delamanid and moxifloxacin -
avoid.
Antidepressants: increase concentrations and
additive antimuscarinic effects, notably with
tricyclics; increased risk of ventricular arrhythmias
with citalopram and escitalopram - avoid; increased
risk of convulsions with vortioxetine.
Antiepileptics: antagonised (convulsive threshold
lowered).
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias with droperidol and pimozide - avoid;
increased risk of ventricular arrhythmias with
risperidone.
Antivirals: concentration possibly increased with
ritonavir; increased risk of ventricular arrhythmias
with saquinavir - avoid.
Anxiolytics and hypnotics: increased sedative effects.
Atomoxetine: increased risk of ventricular
arrhythmias.
Beta-blockers: enhanced hypotensive effect;
increased risk of ventricular arrhythmias with sotalol.
Cytotoxics: increased risk of ventricular arrhythmias
with arsenic trioxide.
Desferrioxamine: avoid concomitant use.
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects
and possibly neurotoxicity.
Pentamidine: increased risk of ventricular
arrhythmias.
Metabolism
Prochlorperazine undergoes extensive first pass metabolism in the gut wall. It is also extensively metabolised in the liver and is excreted in the urine and bile. The metabolites are inactive.
ProchlorperazineSupplier
- Tel
- 86-021-66866686
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- 021-33632979
- info@tsbiochem.com
- Tel
- 025-58849295 18951903616;
- info@adooq.cn
Prochlorperazine(58-38-8)Related Product Information
- 2-Chlorophenothiazine
- Chlorpromazine hydrochloride
- Allyl chloride
- 3-Chloropropyltrimethoxysilane
- Chloromethyl isopropyl carbonate
- Chlorpromazine
- Phenothiazine
- 3-Methyl-2-butanone
- Cyclopropyl methyl ketone
- Xylazine
- 1-Methylpiperazine
- PROCHLORPERAZINE DIMALEATE,Prochlorperazine Dimaleate Also See: P755800,PROCHLORPERAZINE MALEATE,PROCHLORPERAZINE DIMALEATE SALT
- Imiclopazine
- FLUPHENAZINE
- Difluorochloromethane
- Fluphenazine decanoate
- PROCHLORPERAZINE MESYLATE
- Methophenazine